The authors examine existing academic literature on the impact of pharmaceutical mergers and acquisitions and identify remaining gaps.
The pharmaceutical industry often uses mergers and acquisitions strategically to strengthen market positions, expand product portfolios, access new technologies, and enhance innovation capabilities. Regulators are increasingly focusing on the impact of pharmaceutical mergers on innovation, with new merger guidelines issued by the U.S. Justice Department and Federal Trade Commission signaling a more expansive scrutiny of mergers. In this article, authors Penka Kovacheva, Maria Salgado, Anca Cojoc, and Lorenzo Cattivelli examine existing academic literature on the impact of pharmaceutical M&A, highlighting the insights that can be gained from the research and identifying the remaining gaps.
This article was published in Concurrences Competition Law Review in May 2024.
Los Angeles 
